Cencora Inc (COR) Receives Overweight Rating from Barclays
Barclays initiates Overweight coverage on Cencora Inc (COR), reflecting confidence in its market position and growth prospects.
Cencora, Inc. is a pharmaceutical sourcing and distribution services company. The company is headquartered in Conshohocken, Pennsylvania and currently employs 42,000 full-time employees. The firm helps both healthcare providers and pharmaceutical and biotech manufacturers improve patient access to products and enhance patient care. The firm operates through two segments: U.S. Healthcare Solutions and International Healthcare Solutions. The U.S. Healthcare Solutions segment distributes a comprehensive offering of brand-name, specialty brand-name and generic pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to a variety of healthcare providers, including acute care hospitals and health systems, independent and chain retail pharmacies, long-term care and alternate site pharmacies, and other customers. The International Healthcare Solutions segment consists of businesses that focus on international pharmaceutical wholesale and related service operations and global commercialization services.
Latest news, analyst ratings, earnings reports, dividends, insider trades, and market analysis for Cencora Inc.
Last Updated: Dec 11, 2025, 11:06 PM · Source: Finnhub.io
Barclays initiates Overweight coverage on Cencora Inc (COR), reflecting confidence in its market position and growth prospects.
Cencora Inc (COR) announces a $0.60 dividend, reflecting a 9.1% increase.
Cencora Inc (COR) reports Q4 2025 EPS of $3.84, meeting expectations.